Monthly Activities/Appendix 4C Cash Flow Report

• Nitroglycerin 0.4% Ointment approved and launched
• Successful $3.99 million capital raising
• Positive cash flow from operating activities

Acrux Limited (ASX:ACR), a specialty pharmaceuticals group, has released its quarterly cashflow for the three months ended 30 December 2024 along with a business update. Key activities include the approval and launch of Nitroglycerin 0.4% Ointment, the progression of launch planning for Dapsone 7.5% Gel, and the range extension of Dapsone 5% Gel. The company also successfully concluded a Placement and Share Purchase Plan, raising $3.839 million before costs. An Extraordinary General Meeting will be held to seek shareholder approval for the issue of attaching options and shares to Directors. Acrux reported positive Cash Generated from Operating Activities of $0.775 million and an increase in Cash and Cash Equivalents to $3.345 million for the quarter. This was driven by $2.976 million in R&D Tax Incentive receipts, offset by the repayment of a $1.954 million short-term facility. The company's CEO, Michael Kotsanis, highlighted the importance of the newly commercialised products and the capital raising in sustaining the company's future product development aspirations.

Acrux expects increases in customer revenue to be reported in future periods due to the new commercial product activity and the company's other revenue-generating products from its topical generic portfolio.